NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ:EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Exelixis and certain of its officers and/or directors […]
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Anika Therapeutics, Inc. ("Anika" or the "Company") (NASDAQ:ANIK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Anika and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE:NVO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Novo Nordisk and certain of its
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of United Natural Foods, Inc. ("United Natural" or the "Company") (NYSE:UNFI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether United Natural and certain of its
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dyne and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or the "Company") (NASDAQ:EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Edgewise and certain of its officers and/or
NEW YORK, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ:ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CTO Realty Growth, Inc. ("CTO" or the "Company") (NYSE:CTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CTO and certain of its officers
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of National Grid plc ("National Grid" or the "Company") (NYSE:NGG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether National Grid and certain of its
NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of The J.M. Smucker Company ("Smucker" or the "Company") (NYSE:SJM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Smucker and certain of its officers